According to Fintel, on May 16, 2023, HC Wainwright & Co. reiterated its coverage of Onconova Therapeutics (NASDAQ:ONTX) with a Buy recommendation. The one-year price target for Onconova Therapeutics as of May 11, 2023, is expected to increase by 548.31% from its latest reported closing price of 1.18.
Other details show that the projected annual revenue for Onconova Therapeutics is for 0MM, a decrease of 1.76%, while the projected annual non-GAAP EPS is -1.31.
The put/call ratio of ONTX is 0.01, indicating a bullish outlook. There are 35 funds or institutions reporting positions in Onconova Therapeutics, which is a decrease of 3 owner(s) or 7.89% in the last quarter. Average portfolio weight of all funds dedicated to ONTX is 0.00%, a decrease of 7.91%. Total shares owned by institutions decreased to 1,457K shares in the last three months by 15.25%.
VTSMX – Vanguard Total Stock Market Index Fund Investor Shares holds 366K shares representing 1.74% ownership of the company, while VEXMX – Vanguard Extended Market Index Fund Investor Shares holds 237K shares representing 1.13% ownership of the company. Geode Capital Management holds 170K shares representing 0.81% ownership of the company. Renaissance Technologies holds 145K shares representing 0.69% ownership of the company.
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.
The opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.